HC Wainwright Expects Lower Earnings for Abeona Therapeutics

Abeona Therapeutics Inc (NASDAQ:ABEO) – HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Abeona Therapeutics in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19.

A number of other research analysts have also recently commented on ABEO. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Oppenheimer began coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $5.04 on Wednesday. The company’s fifty day moving average price is $5.42 and its 200-day moving average price is $5.81. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market capitalization of $219.09 million, a price-to-earnings ratio of -1.87 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45.

Hedge Funds Weigh In On Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in ABEO. Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics during the third quarter valued at about $151,000. Citigroup Inc. boosted its holdings in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 56,332 shares during the period. Western Standard LLC grew its position in Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Jane Street Group LLC bought a new position in Abeona Therapeutics during the 3rd quarter worth approximately $84,000. Finally, XTX Topco Ltd purchased a new position in Abeona Therapeutics in the 3rd quarter worth approximately $160,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.